13.33

3.68% -0.51

After Hours: 13.33

Third Harmonic Bio Inc (THRD)

Overview News Price History Option Chain Financials Discussions Forecast

Third Harmonic Bio Inc stock is currently priced at $13.33, with a 24-hour trading volume of 46,525. It has seen a -3.68% decreased in the last 24 hours and a +3.25% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $13.76 pivot point. If it approaches the $13.17 support level, significant changes may occur.

Previous Close:

$13.84

Open:

$13.87

24h Volume:

46,525

Market Cap:

$545.86M

Revenue:

Net Income/Loss:

$-30.82M

P/E Ratio:

-8.4807

EPS:

-1.5718

Net Cash Flow:

$-20.43M

1W Performance:

-6.19%

1M Performance:

+3.25%

6M Performance:

+26.47%

1Y Performance:

+163.44%

1D Range:

$13.31

$14.05

52W Range:

$4.7249

$16.94

Third Harmonic Bio Inc Stock (THRD) Company Profile

Name

Third Harmonic Bio Inc

Sector

Healthcare (1204)

Industry

Biotechnology (696)

Phone

617-915-6680

Address

300 Technology Square, 8th Floor, Cambridge

Employee

Twitter

Next Earnings Date

Latest SEC Filings

THRD's Discussions on Twitter

Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-16-22	Downgrade	Jefferies	Buy → Hold
Dec-15-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-10-22	Initiated	Cowen	Outperform
Oct-10-22	Initiated	Jefferies	Buy
Oct-10-22	Initiated	Morgan Stanley	Overweight

Third Harmonic Bio Inc Stock (THRD) Latest News

Third harmonic exec sells $7k in stock, exercises options By Investing.com - Investing.com

Investing.com

Raymond James Initiates Coverage of Third Harmonic Bio (THRD) with Outperform Recommendation - MSN

MSN

Raymond James Initiates Coverage of Third Harmonic Bio (THRD) with Outperform Recommendation - MSN

MSN

Third Harmonic Bio Announces Executive Changes and Voting Results - TipRanks.com - TipRanks

TipRanks

When the Price of (THRD) Talks, People Listen - Stock Traders Daily

Stock Traders Daily

Electra Therapeutics Builds Leadership Team with Appointment of Dr. Graham Parry as Chief Scientific Officer and Dr ... - Lelezard

Lelezard

Third Harmonic Bio Inc Stock (THRD) Financials Data

Third Harmonic Bio Inc (THRD) Net Income 2024

THRD net income (TTM) was -$30.82 million for the quarter ending December 31, 2023, a +12.32% increase year-over-year.

Third Harmonic Bio Inc (THRD) Cash Flow 2024

THRD recorded a free cash flow (TTM) of -$20.43 million for the quarter ending December 31, 2023, a +41.50% increase year-over-year.

Third Harmonic Bio Inc (THRD) Earnings per Share 2024

THRD earnings per share (TTM) was -$0.95 for the quarter ending December 31, 2023, a +41.07% growth year-over-year.

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.